| Lantus SoloStar 100 units/ml solution for injection in a pre-filled pen EU/1/00/134/030-037 |
Insulin glargine |
Sanofi-Aventis Deutschland GmbH |
— |
| LEMTRADA 12 mg concentrate for solution for infusion EU/1/13/869/001 |
Alemtuzumab |
Sanofi Belgium |
— |
| Maalox 200mg/175mg per 5ml Oral Suspension PA23180/009/001 |
Magnesium hydroxide, Aluminium hydroxide |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Maalox 400mg/400mg Chewable Tablets PA23180/009/002 |
Magnesium hydroxide, Aluminium oxide, hydrated |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Maalox Plus 200 mg/175 mg/25 mg Oral Suspension PA23180/008/001 |
Aluminium hydroxide, Magnesium hydroxide, Simeticone |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Maalox Plus Chewable Tablets 200 mg/200 mg/25 mg PA23180/008/002 |
ALUMINIUM OXIDE, HYDRATED PH. EUR, MAGNESIUM HYDROXIDE PH. EUR., Dimeticone ph. eur. (as simeticone ph. eur.) |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Maci EU/1/13/847/001 |
Autologous chondrocytes |
Sanofi B.V. |
— |
| MenQuadfi solution for injection EU/1/20/1483/001-002 |
Neisseria Meningitidis Group A Polysaccharide, Neisseria Meningitis Group W135 Polysaccharide, N. Meningitidis Group Y Polysaccharide, Tetanus toxoid, N. Meningitidis Group C Polysaccharide |
Sanofi Winthrop Industrie |
— |
| MULTAQ 400 mg film-coated tablets EU/1/09/591/1-4 |
Dronedarone hydrochloride |
Sanofi Winthrop Industrie |
— |
| Myozyme 50 mg powder for concentrate for solution for infusion EU/1/06/333/1-3 |
Alglucosidase alfa |
Sanofi B.V. |
— |
| NASACORT 55 micrograms/dose, nasal spray, suspension PA23180/001/001 |
Triamcinolone acetonide |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Nasacort Allergy 55 micrograms/dose nasal spray, suspension PA23180/001/002 |
Triamcinolone acetonide |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Nexviadyme 100 mg powder for concentrate for solution for infusion EU/1/21/1579/001-004 |
Avalglucosidase Alfa |
Sanofi B.V. |
— |
| Nuvaxovid dispersion for injection COVID-19 Vaccine (recombinant, adjuvanted) EU/1/21/1618/001 |
SARS-CoV-2 spike protein recombinant |
Sanofi Winthrop Industrie |
— |
| Phenergan 25 mg film-coated tablets PA23180/011/002 |
Promethazine hydrochloride |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Phenergan 5 mg/5 ml oral solution PA23180/011/001 |
Promethazine hydrochloride |
Opella Healthcare France SAS T/A Sanofi |
Marketed |
| Plaquenil 200mg Film-coated Tablets PA0540/155/001 |
Hydroxychloroquine sulfate |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Plavix 300 mg film-coated tablets EU/1/98/069/008-010 |
Clopidogrel hydrogensulfate |
Sanofi Winthrop Industrie |
— |
| Plavix 75 mg film-coated tablets EU/1/98/069/001-007 |
Clopidogrel hydrogensulfate |
Sanofi Winthrop Industrie |
— |
| Praluent 150 mg solution for injection in pre-filled pen EU/1/15/1031/007-009 |
Alirocumab |
Sanofi-Aventis Groupe |
— |
| Praluent 150 mg solution for injection in pre-filled syringe EU/1/15/1031/010-012 |
Alirocumab |
Sanofi-Aventis Groupe |
— |
| Praluent 300 mg solution for injection in pre-filled pen EU/1/15/1031/019-020 |
Alirocumab |
Sanofi-Aventis Groupe |
— |
| Praluent 75 mg solution for injection in pre-filled pen EU/1/15/1031/001-003 |
Alirocumab |
Sanofi-Aventis Groupe |
— |
| Praluent 75 mg solution for injection in pre-filled syringe EU/1/15/1031/004-006 |
Alirocumab |
Sanofi-Aventis Groupe |
— |
| Quadrivalent Influenza Vaccine (split virion, inactivated), suspension for injection in pre-filled syringe Quadrivalent influenza vaccine (split virion, inactivated) PA23458/010/001 |
A/Victoria/4897/2022 (H1N1)pdm09-like strain (A/Victoria/4897/2022, IVR-238, B/Austria/1359417/2021 - like strain (B/Michigan/01/2021, wild type), B/PHUKET/3073/2013 -LIKE STRAIN (B/PHUKET/3073/2013, WILD TYPE), Influenza A virus, A/Croatia/10136RV/2023 (H3N2) like strain X-425A, Inactivated |
Sanofi Winthrop Industrie |
Not marketed |
| Renagel EU/1/99/123/006 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renagel EU/1/99/123/007 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renagel EU/1/99/123/009 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renagel EU/1/99/123/010 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renagel EU/1/99/123/011-013 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renagel 400 mg Film-coated tablet EU/1/99/123/005-007 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renagel 800 mg Film-coated tablet EU/1/99/123/008-013 |
Sevelamer |
Sanofi Winthrop Industrie |
— |
| Renvela 0.8 g Powder for oral suspension EU/1/09/521/008-009 |
Sevelamer carbonate |
Sanofi Winthrop Industrie |
— |
| Renvela 0.8 g Powder for oral suspension (with dosing spoon) EU/1/09/521/009 |
Sevelamer carbonate |
Sanofi Winthrop Industrie |
— |
| Renvela 1.6 g Powder for oral suspension EU/1/09/521/4-5 |
Sevelamer carbonate |
Sanofi Winthrop Industrie |
— |
| Renvela 2.4 g Powder for oral suspension EU/1/09/521/6-7 |
Sevelamer carbonate |
Sanofi Winthrop Industrie |
— |
| Renvela 800 mg Film-coated tablet EU/1/09/521/1-3 |
Sevelamer carbonate |
Sanofi Winthrop Industrie |
— |
| REPEVAX, suspension for injection, in pre-filled syringe Diphtheria, Tetanus, Pertussis (acellular, component) and Poliomyelitis (inactivated) Vaccine (adsorbed, reduced antigen(s) content) PA23458/004/001 |
Tetanus toxoid, Diphtheria toxoid, Pertussis toxoid, Filamentous haemagglutinin, Pertactin |
Sanofi Winthrop Industrie |
Not marketed |
| REVAXIS Suspension for injection in pre-filled syringe Diphtheria, tetanus and poliomyelitis (inactivated) vaccine (adsorbed, reduced antigen(s) content) PA23458/005/001 |
Diphtheria toxoid, Tetanus toxoid, POLIOVIRUS, TYPE 1, Poliovirus, type 2, Poliovirus, type 3 |
Sanofi Winthrop Industrie |
Marketed |
| Rifadin 100 mg/5 ml Oral Suspension PA0540/066/004 |
Rifampicin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Rifadin 150mg Capsules PA0540/066/001 |
Rifampicin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Rifadin 300mg Capsules PA0540/066/002 |
Rifampicin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Rifadin Intravenous 600mg Powder and Solvent for Concentrate for Solution for Infusion PA0540/066/003 |
Rifampicin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Rifater 50 mg/300 mg/120 mg Tablets PA0540/067/001 |
Isoniazid, Pyrazinamide, Rifampicin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Rifinah 150/100 mg Film- Coated Tablets PA0540/068/001 |
Rifampicin, Isoniazid |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Rifinah 300/150 mg Film Coated Tablets PA0540/068/002 |
Rifampicin, Isoniazid |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| RILUTEK 50 mg film-coated tablets EU/1/96/010/001 |
Riluzole |
Sanofi Winthrop Industrie |
— |
| Sabril 500 mg film-coated Tablets PA0540/023/001 |
Vigabatrin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| Sabril 500 mg Granules for Oral Solution PA0540/023/002 |
Vigabatrin |
Sanofi-Aventis Ireland Limited T/A SANOFI |
Marketed |
| SARCLISA 20 mg/mL concentrate for solution for infusion EU/1/20/1435/001-003 |
Isatuximab |
Sanofi Winthrop Industrie |
— |